Exact Mass: 357.18747320000006
Exact Mass Matches: 357.18747320000006
Found 85 metabolites which its exact mass value is equals to given mass value 357.18747320000006,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
(S)-Laudanosine
C21H27NO4 (357.19399820000007)
(S)-Laudanosine is found in opium poppy. (S)-Laudanosine is an alkaloid from Papaver somniferum (opium poppy Alkaloid from Papaver somniferum (opium poppy). (S)-Laudanosine is found in opium poppy. D002491 - Central Nervous System Agents DL-Laudanosine, an Atracurium and Cisatracurium metabolite, crosses the blood–brain barrier and may cause excitement and seizure activity[1]. DL-Laudanosine, an Atracurium and Cisatracurium metabolite, crosses the blood–brain barrier and may cause excitement and seizure activity[1].
Nalbuphine
C21H27NO4 (357.19399820000007)
Nalbuphine is only found in individuals that have used or taken this drug. It is a narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. [PubChem]The exact mechanism of action is unknown, but is believed to interact with an opiate receptor site in the CNS (probably in or associated with the limbic system). The opiate antagonistic effect may result from competitive inhibition at the opiate receptor, but may also be a result of other mechanisms. Nalbuphine is thought primarily to be a kappa agonist. It is also a partial mu antagonist analgesic, with some binding to the delta receptor and minimal agonist activity at the sigma receptor. D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AF - Morphinan derivatives D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics
5-hydroxypropafenone
C21H27NO4 (357.19399820000007)
5-hydroxypropafenone is a metabolite of propafenone. Propafenone is a class of anti-arrhythmic medication, which treats illnesses associated with rapid heart beats such as atrial and ventricular arrhythmias. (Wikipedia) D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents
(E)-(4-Acetoxycinnamoyl)-epilupinine
C21H27NO4 (357.19399820000007)
N-(naphthalen-1-yl)-2-pentyl-2h-indazole-3-carboxamide
(2S)-[(2S)-aminopropionylamino]-5-{[(3S)-((1S)-methylpropyl)-4-oxooxetane-(2R)-carbonyl]amino}pentanoic acid|belactosin C
methyl 4-((E)-2-acetyl-4-oxonon-1-enyl)-6-((E)-prop-1-enyl)nicotinate|monascopyridine E|Monasnicotinate A
C21H27NO4 (357.19399820000007)
Laudanosine
C21H27NO4 (357.19399820000007)
D002491 - Central Nervous System Agents Annotation level-1 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.628 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.624 Acquisition and generation of the data is financially supported by the Max-Planck-Society IPB_RECORD: 2441; CONFIDENCE confident structure DL-Laudanosine, an Atracurium and Cisatracurium metabolite, crosses the blood–brain barrier and may cause excitement and seizure activity[1]. DL-Laudanosine, an Atracurium and Cisatracurium metabolite, crosses the blood–brain barrier and may cause excitement and seizure activity[1].
nalbuphine
C21H27NO4 (357.19399820000007)
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AF - Morphinan derivatives D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics
5-hydroxypropafenone
C21H27NO4 (357.19399820000007)
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents
Laudanoside
C21H27NO4 (357.19399820000007)
Origin: Plant; Formula(Parent): C21H27NO4; Bottle Name:Laudanosine; PRIME Parent Name:Laudanosine; PRIME in-house No.:V0357; SubCategory_DNP: Isoquinoline alkaloids, Morphine alkaloids
butyl prop-2-enoate,prop-2-enenitrile,prop-2-enoic acid,styrene
C21H27NO4 (357.19399820000007)
Cafedrine
C18H23N5O3 (357.18008080000004)
C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides > C01CA - Adrenergic and dopaminergic agents D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
Setastine
C22H28ClNO (357.18593080000005)
C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist
2-({6-[(3R)-3-Amino-1-piperidinyl]-3-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl}methyl)benzamide
C18H23N5O3 (357.18008080000004)
9-[3-(CIS-3,5-DIMETHYL-1-PIPERAZINYL)PROPYL]CARBAZOLE MONOHYDROCHLORIDE
C21H28ClN3 (357.19716380000006)
Olorinab
C18H23N5O3 (357.18008080000004)
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
(R)-laudanosine
C21H27NO4 (357.19399820000007)
A benzylisoquinoline alkaloid that is (R)-tetrahydropapaverine in which the amino hydrogen has been replaced by a methyl group
N-[[(1R,2R)-3-Oxo-2-[(Z)-2-pentenyl]cyclopentan-1-yl]acetyl]-L-phenylalanine
C21H27NO4 (357.19399820000007)
N-[[(1R)-3-Oxo-2alpha-[(Z)-2-pentenyl]cyclopentane-1alpha-yl]acetyl]-L-phenylalanine
C21H27NO4 (357.19399820000007)
(2S)-2-[[2-[3-oxo-2-[(Z)-pent-2-enyl]cyclopentyl]acetyl]amino]-3-phenylpropanoic acid
C21H27NO4 (357.19399820000007)
1-cyclopentyl-1-[(5,8-dimethyl-2-oxo-1H-quinolin-3-yl)methyl]-3-ethylthiourea
C20H27N3OS (357.18747320000006)
(4R,4aS,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol
C21H27NO4 (357.19399820000007)
(4R,4aS,7S,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol
C21H27NO4 (357.19399820000007)
N-[6-(2-amino-4-fluoroanilino)-6-oxohexyl]-4-methylbenzamide
2-(Phenylmethyl)-5-[4-(phenylmethyl)-1-piperidinyl]-4-oxazolecarbonitrile
6-Amino-2-methyl-8-(4-propan-2-ylphenyl)-1,3,8,8a-tetrahydroisoquinoline-5,5,7-tricarbonitrile
N-[2-[[4-(2-hydroxyethylamino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]phenyl]acetamide
4-[[(1R,5S)-7-[4-[(E)-2-phenylethenyl]phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]methyl]-1,3-oxazole
(S)-Laudanosine
C21H27NO4 (357.19399820000007)
D002491 - Central Nervous System Agents
(1r,3r,4s,5s,8r,9s,11s,14s,17s,18r)-3,4-dihydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,16-dione
C21H27NO4 (357.19399820000007)
dimethyl(2-{4,13,14-trimethoxy-2-oxatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,12,14-hexaen-7-yl}ethyl)amine
C21H27NO4 (357.19399820000007)
(1r)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinoline
C21H27NO4 (357.19399820000007)
5-hydroxy-4-(1-hydroxy-2,4-dimethyloct-6-en-1-ylidene)-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one
C21H27NO4 (357.19399820000007)
(2s)-2-{[(2s)-2-amino-1-hydroxypropylidene]amino}-5-({[(2r,3s)-3-[(2s)-butan-2-yl]-4-oxooxetan-2-yl](hydroxy)methylidene}amino)pentanoic acid
(4e)-5-hydroxy-4-[(6e)-1-hydroxy-2,4-dimethyloct-6-en-1-ylidene]-2-[(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one
C21H27NO4 (357.19399820000007)
methyl 4-(2-acetyl-4-oxonon-1-en-1-yl)-6-(prop-1-en-1-yl)pyridine-3-carboxylate
C21H27NO4 (357.19399820000007)
(1r,3r,4s,5r,8r,9s,11s,14r,17s,18r)-3,4-dihydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,16-dione
C21H27NO4 (357.19399820000007)
2-[(2-amino-1-hydroxypropylidene)amino]-5-({hydroxy[4-oxo-3-(sec-butyl)oxetan-2-yl]methylidene}amino)pentanoic acid
(1s,9ar)-octahydro-1h-quinolizin-1-ylmethyl (2e)-3-[4-(acetyloxy)phenyl]prop-2-enoate
C21H27NO4 (357.19399820000007)
methyl 4-[(1e)-2-acetyl-4-oxonon-1-en-1-yl]-6-[(1e)-prop-1-en-1-yl]pyridine-3-carboxylate
C21H27NO4 (357.19399820000007)
(1r,3r,4s,5s,8r,9s,11s,17s,18r)-3,4-dihydroxy-5,7-dimethyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,16-dione
C21H27NO4 (357.19399820000007)